ETFIQData as of Nov 19, 2026. · etfiq.com/funds/canc

CANC Fact Sheet: Tema Oncology ETF

Share
$37.52
close, Nov 20, 2026

Over the year to Nov 19, 2026, CANC returned +13.0% in total and charged 0.75% a year.

1-year total return
+10.3%
to Nov 20, 2026
Expense ratio
0.75%
a year
Net assets
$198m
on Nov 19, 2026
Net flow, last 5 trading days
+$2.1m
daily basis to Nov 19, 2026

Growth of $10,000, 1 year

CANC $11,296 +13.0% · VOO $11,147 +11.5% · Total return, distributions reinvested, Nov 19, 2025 to Nov 19, 2026.

Returns

WindowTotal return
1 month−9.7%
3 months−15.9%
Year to date+8.1%
1 year+10.3%
3 years+69.8%

Total return, distributions reinvested, each window to Nov 20, 2026.

Ten largest positions

HoldingWeight
GENMAB A/S6.47%
REVOLUTION MEDICINES INC5.54%
ELI LILLY & CO5.13%
COGENT BIOSCIENCES INC4.47%
BEONE MEDICINES LTD4.45%
MERCK & CO INC4.35%
EXELIXIS INC3.82%
CG ONCOLOGY INC3.76%
NOVARTIS AG3.74%
ABBVIE INC3.48%

CANC top ten by weight, 45.2% of the fund, of its 54 equity positions, from the holdings published by its issuer for Nov 19, 2026.

Facts

Holds 54 stocks in therapeutics and medical devices, 20% of its weight in S&P 500 companies · First traded Aug 15, 2023 · Benchmark Its own holdings, as of Nov 19, 2026

Source: ETFIQ, from issuer disclosures, SEC filings and exchange prices. Returns from daily closes, distributions reinvested; each number is dated beside it, and every one is on the fund’s page.Cite as: ETFIQ, CANC Fact Sheet: Tema Oncology ETF. Data as of Nov 19, 2026. https://etfiq.com/funds/canc/fact-sheet/ETFIQ is an independent publisher. Not an issuer, broker or adviser. No recommendations. Printed from etfiq.com/funds/canc.